Supernus Pharmaceuticals, Inc.
SUPN
Rang în acțiuni
#5708
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to... Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.
Preț acțiune
$39.56
Capitalizare de piață
$2.30B
Schimbare (1 zi)
4.44%
Schimbare (1 an)
-19.63%
Țară
US
Tranzacționează Supernus Pharmaceuticals, Inc. (SUPN)
Categorie
Healthcare
Istoric dividende pentru Supernus Pharmaceuticals, Inc. (SUPN)
Supernus Pharmaceuticals, Inc. (simbol acțiune: SUPN) a efectuat un total de 0 plăți de dividende.
Suma tuturor dividendelor (ajustată pentru split-uri de acțiuni) este: 0.00
Randamentul dividendului (TTM): 0
Suma tuturor dividendelor (ajustată pentru split-uri de acțiuni) este: 0.00
Randamentul dividendului (TTM): 0
Plăți de dividende pentru Supernus Pharmaceuticals, Inc. (SUPN) din 2026 până în 2026
Plăți anuale de dividende
| An | Dividend (ajustat pentru split de acțiuni) | Schimbă |
|---|---|---|
| Nu sunt suficiente date pentru perioada selectată. | ||
Lista tuturor plăților de dividende
| An | Dividend | Schimbă |
|---|---|---|
| Nu sunt suficiente date pentru perioada selectată. | ||
Dividende ale companiilor similare sau concurente
| Companie | Număr de plăți de dividende | Țara |
|---|---|---|
| 0.00% |
DE
|
|
| 0.00% |
DE
|
|
| 0.00% |
JP
|
|
| 0.00% |
CH
|
|
| 38.00% |
IN
|
